Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes

Lee, You-Bin; Hwang, Hwan Jin; Kim, Jung A; Hwang, Soon Young; Roh, Eun; Hong, So Hyeon; Choi, Kyung Mook; Baik, Sei-Hyun; Yoo, Hye Jin

doi:10.1177/1479164119860746

Cited by 17 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intriguingly, FAM19A5 mRNA and protein levels are significantly down-regulated in obese and diabetic animals 3 , suggesting a causal relationship between decreased FAM19A5 levels and metabolic disease conditions. However, this result is in part contradictory to a recent observation in humans where individuals with type 2 diabetes had higher FAM19A5 serum levels than those without type 2 diabetes 9 . The public database for human tissue RNA expression reports that FAM19A5 is expressed in the female and male reproductive tissues including the ovaries, uterus, and testis, although absolute levels in these tissues are significantly lower than brain tissue levels 4,10 .…”

Section: Introductioncontrasting

confidence: 99%

Is FAM19A5 an adipokine? Peripheral FAM19A5 in wild-type, FAM19A5 knockout, and LacZ knockin mice

Kwak¹,

Cho²,

Cho³

et al. 2020

Preprint

View full text Add to dashboard Cite

FAM19A5 (also called TAFA5) is a novel secretory protein that is primarily expressed in the brain. However, a recent study reported that FAM19A5 is an adipocyte-derived adipokine that regulates vascular smooth muscle function. Furthermore, genome-wide association study (GWAS) and RNA-seq analyses revealed that the FAM19A5 was associated with a variety of diseases and tumorigenesis in peripheral tissues. We investigated FAM19A5 transcript and protein levels in the FAM19A5 peripheral expression 2 peripheral tissues, including adipose tissues from wild-type, FAM19A5 knock-out, and LacZ knock-in mice. In general, total FAM19A5 transcript levels in the central and peripheral nervous systems were higher than levels in any of the peripheral tissues including adipose tissues. Brain tissues expressed similar levels of the FAM19A5 transcript isoforms 1 and 2, whereas expression in the peripheral tissues predominantly expressed isoform 2. In the peripheral tissues, but not the brain, FAM19A5 protein levels in adipose and reproductive tissues were below detectable limits for analysis by Western blot. Additionally, we found that FAM19A5 protein did not interact with the S1PR2 receptor for G-protein-mediated signal transduction, β-arrestin recruitment, and ligandmediated internalization. Instead, FAM19A5 was internalized into HEK293 cells in an extracellular matrix protein-dependent manner. Taken together, the present study determined basal levels of FAM19A5 transcripts and proteins in peripheral tissues, which provides compelling evidence to further investigate the function of FAM19A5 in peripheral tissues under pathological conditions, including metabolic diseases and/or tumorigenesis.

show abstract

Section: Introductioncontrasting

confidence: 99%

Is FAM19A5 an adipokine? Peripheral FAM19A5 in wild-type, FAM19A5 knockout, and LacZ knockin mice

Kwak¹,

Cho²,

Cho³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Wang et al showed FAM19A5 inhibits the vascular smooth muscle cells proliferation and ameliorates neointima formation in the injured rat carotid arteries (8). Although several studies addressed contribution of FAM19A5 to neurological disorders (19)(20)(21)(22)(23), existing data on a relevant association of FAM19A5 and cardiac and metabolic disorders are very limited (8,9). To our knowledge, this is the first clinical observation pointing to the association of FAM19A5 with the pathogenesis of NAFLD.…”

Section: Introductionmentioning

confidence: 81%

“…These results are in agreement with our ndings which showed lower circulating levels of FAM19A5 in NAFLD. However, Lee et al reported higher serum levels of FAM19A5 in diabetic patients compared to nondiabetic subjects (9). These inconsistent ndings might be related to the different inclusion and exclusion criteria used in various human studies.…”

Section: Discussionmentioning

confidence: 97%

“…In a recent clinical study, it has been indicated that circulating level of FAM19A5 is different in diabetic patients compared to controls. They also found association of FAM19A5 with the obesity and diabetes indicators (9).…”

Section: Introductionmentioning

confidence: 91%

“…The sample size was calculated based on data from a previous study about circulating levels of FAM19A5 in the subjects with and without diabetes (9). We calculated that 32 subjects in each group would provide 90% power to achieve a difference of 80% in the circulating levels of FAM19A5 between the studied groups assuming a 2-sided t-test with alpha of 0.05.…”

Section: Statistical Analysesmentioning

confidence: 99%

See 2 more Smart Citations

Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease

Yari

Shabani

Karami

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Family with sequence similarity 19 (chemokine (C-C motif)-like) member A5 (FAM19A5) is a newly identified adipokine. There is a limited number of studies linking FAM19A5 to metabolic disorders. In the current study, we aimed to explore if FAM19A5 is associated with nonalcoholic fatty liver disease (NAFLD). We also sought to determine the possibility of FAM19A5 association with subclinical atherosclerosis in NAFLD patients. Methods: A total of 69 subjects including 37 NAFLD and 32 control subjects were included in this cross-sectional study. Plasma concentration of FAM19A5 was measured with the ELISA method. Carotid artery intima-media thickness (cIMT) was assessed by the ultrasonography.Results: Plasma concentration of FAM19A5 in patients with NAFLD was significantly lower in NAFLD patients than controls. Moreover, we observed significant negative correlations between plasma level of FAM19A5 and body mass index (BMI), visceral fat, alanine amino transferase (ALT), aspartate amino transferase (AST), liver stiffness (LS), and cIMT. Following stepwise multiple linear regression analysis, ALT and cIMT were the only determinants of FAM19A5 level. Conclusions: This is the first report to describe association of circulating FAM19A5 levels with NAFLD. Our findings provide further evidence showing relation of FAM19A5 with the risk of atherosclerosis. However, more studies are necessary to unravel the contribution of lower FAM19A5 levels to the NAFLD pathogenesis and the higher risk of atherosclerosis in these patients.

show abstract

Impacts of a 12-week aerobic, resistance, and combined exercise training on serum FAM19A5, glucose homeostasis, and novel cardiovascular risk factors among adults with obesity

Mir,

Shamseddini,

Rahimi

et al. 2024

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes

Cited by 17 publications

References 28 publications

Is FAM19A5 an adipokine? Peripheral FAM19A5 in wild-type, FAM19A5 knockout, and LacZ knockin mice

Is FAM19A5 an adipokine? Peripheral FAM19A5 in wild-type, FAM19A5 knockout, and LacZ knockin mice

Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease

Impacts of a 12-week aerobic, resistance, and combined exercise training on serum FAM19A5, glucose homeostasis, and novel cardiovascular risk factors among adults with obesity

Contact Info

Product

Resources

About